文献速递慢病管理预防保健、筛查与疫苗

多病共存患者一级预防中的他汀处方决策:全科医生的定性分析

Statins for primary prevention in multimorbid patients: to prescribe or not to prescribe? A qualitative analysis of general practitioners' decision-making processes.
PubMed 文献 · Fam Pract · 2025-01-01

结果发现糖尿病是特定动机,全科医生区分心血管与非心血管多病共存,专家型处方者整合心血管风险评分,非专家型偏好经验法则,他汀在多病共存患者中仍处方不足。

要点

  • 糖尿病是多病共存患者考虑他汀一级预防的特定动机。
  • 全科医生在决策中区分心血管与非心血管多病共存。
  • 专家型处方者整合风险评分,非专家型偏好经验法则。

核心结论

  • 他汀在多病共存患者一级预防中处方不足,非糖尿病多病共存患者处方几率更低。
  • 建议将风险评估评分作为决策辅助工具,支持个性化共享决策讨论。

研究设计与样本

  • 采用基于演绎框架和归纳分析的方法,框架综合循证医学、MOT模型、理论域框架和共享决策框架。

主要发现

  • 糖尿病似乎是决定他汀一级预防处方的特定动机。
  • 全科医生在多病共存情境下区分心血管与非心血管多病共存。
  • 专家型处方者整合心血管风险计算评分,非专家型认为评分难以解读并偏好经验法则。
  • 一名受访者将风险计算评分作为与患者讨论他汀处方的支持工具。

临床怎么用

  • 全科医生应关注多病共存患者他汀一级预防的处方不足问题。
  • 可考虑将心血管风险评估评分作为共享决策的辅助工具。
  • 针对非糖尿病多病共存患者,需个性化讨论他汀处方。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A better understanding of the determinants involved in general practitioners' (GPs) decision-making processes when it comes to prescribing statins as primary prevention in patients with multimorbidity could provide insights for improving implementation of primary prevention guidelines. METHODS: We conducted a qualitative study using a deductive framework-based and inductive analysis of GPs' semi-structured interviews verbatim, from which expertise profiles of prescribers were also drawn. The analytical framework was built from a pragmatic synthesis of the evidence-based medicine, Modelling using Typified Objects (MOT) model of clinical reasoning processes, Theoretical Domains Framework, and shared decision-making frameworks. RESULTS: Fifteen GPs were interviewed between June 2019 and January 2020. Diabetes seemed to represent a specific motivation for deciding about statin prescription for primary prevention purposes; and in situations of multimorbidity, GPs differentiated between cardiovascular and non-cardiovascular multimorbidity. Expert prescribers seemed to have integrated the utilisation of cardiovascular risk calculation scores throughout their practice, whereas non-expert prescribers considered them difficult to interpret and preferred using more of a "rule of thumb" process. One interviewee used the risk calculation score as a support for discussing statin prescription with the patient. CONCLUSION: Our results shed light on the reasons why statins remain under-prescribed for primary prevention and why non-diabetic multimorbid patients have even lower odds of being prescribed a statin. They call for a change in the use of risk assessment scores, by placing them as decision aids, to support and improve personalised shared decision-making discussions as an efficient approach to improve the implementation of recommendations about statins for primary prevention.

来源:Fam Pract,查看原文。版权归原作者所有。

引用

  1. Onaisi R, Bezzazi A, Berthouin T, et al. Statins for primary prevention in multimorbid patients: to prescribe or not to prescribe? A qualitative analysis of general practitioners' decision-making processes. Fam Pract. 2025. PMID: 37463339. doi:10.1093/fampra/cmad068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。